30Jan
Webinar

Thursday 30 January

“Isn’t it obvious?” Understanding and beating the USPTO’s most common art-based rejection

When and where

Date and time

Start: Thursday 30 January 2020, 12:30 PM

End: Thursday 30 January 2020, 01:30 PM

Event Overview

The ability to overcome obviousness rejections under 35 U.S.C. 103 before the USPTO is a key skill for patent practitioners. Recent USPTO statistics show that obviousness rejections are issued in 79% of office actions with at least one rejection. How can you win key patent rights for your clients as anticipation rejections wane in popularity and frequency, and obviousness rejections rage? We will discuss obviousness at a foundational level and progress to drafting strategies and practice tips to help you overcome obviousness at the USPTO.

Audience

Fellows, Students

Speakers

Loren Hulse, Holland & Hart

Loren Hulse, Holland & Hart

As a practitioner, Loren has developed, managed, and protected both large and small domestic and foreign patent and trademark portfolios. His wide-ranging biotech and pharmaceutical experience includes advising clients how to protect small molecule and peptide drugs, methods of treatment, genetic constructs and therapies, nucleotide analogs, and RNA related drug technologies. He has also counseled clients developing medical devices such as optically-guided feeding tubes, injectors, diagnostic kits, catheters, and cardiac assist devices. In the chemical arena, Loren’s experience includes assisting clients to protect solid oxide fuel cell technologies, ionically-conductive membrane applications, and syngas production techniques.

The event has been added to your basket:

“Isn’t it obvious?” Understanding and beating the USPTO’s most common art-based rejection

Proceed to basket

Shopping Basket

No products in the cart.

Are you a CIPA member?

Sign in to your account to register for the event

Forgotten password?

If you are not yet registered or a member of CIPA, please register here

Skip to content